TNKASE (tenecteplase) / Roche, Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12345678910111213...1415»
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Current State Of Acute Stroke Thrombolysis In The MT2020+ Caribbean Region (Hall F, Poster Hall; MP48) -  Feb 7, 2023 - Abstract #ISC2023ISC_1421;    
    This this survey brings light to an enormous disparity in care of stroke patients around the world, specifically in the MT2020+ Caribbean region. We create a valid tool can be used to assess local access to thrombolytic.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    095: The Road to Tenecteplase in Routine Clinical Practice (Ballroom D1 / D2) -  Feb 7, 2023 - Abstract #ISC2023ISC_1213;    
    Do the 4 recent TNK trials provide enough evidence? This session will tackle these challenging questions.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Transition To Tenecteplase From Alteplase Improves Ambulance And Interfacility Transfer Time Metrics In A Large Regional Healthcare System (Room D163 / D165 / D170 / D172; In Person) -  Feb 7, 2023 - Abstract #ISC2023ISC_1028;    
    58.5% of the TNK cases had a DIDO of ≤ 90 minutes vs 34.4% of tPA cases.|Conclusions Switching from IV-tPA to IV-TNK improved the DIDO by 33 minutes. This improvement was driven by two novel DIDO metrics: Door to Ambulance Arrival Time (DAA) and Ambulance Arrival to Ambulance Departure Time (AAAD) likely because the absence of a tPA infusion (drip & ship) allowed the use of non-critical care ambulances, which are more widely available, to transport patients.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Driving Down Door To Needle Time: ED Stroke Leadership's Commitment To Continuous Improvement (Hall F, Poster Hall; P31) -  Feb 7, 2023 - Abstract #ISC2023ISC_727;    
    In addition to changing the IV thrombolytic from alteplase to tenecteplase, the team took the opportunity to make additional changes to the process and provided education of the stroke protocols and measures to the staff. In conclusion, the ED Stroke Leadership Team’s commitment to continuous improvement has been the driving factor in the reduction of the EMS Door to Needle time.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Tenecteplase Vs Alteplase For Large Vessel Occlusion Stroke: A Systematic Review And Meta-analysis (Hall F, Poster Hall; P1) -  Feb 7, 2023 - Abstract #ISC2023ISC_695;    
    Tenecteplase, as compared to alteplase, increases the odds of functional improvement and excellent outcome. These findings support bridging tenecteplase in patients with LVO.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Health-related Quality Of Life After Thrombolysis In Acute Stroke: Results From The Act Trial (Hall F, Poster Hall; MP11) -  Feb 7, 2023 - Abstract #ISC2023ISC_573;    
    There is no differential effect of the type of thrombolysis on patient-reported global HRQOL and health state utilities of acute stroke patients. Disparities in HRQOL were mainly explained by sex, age, and disease severity.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Tenecteplase Versus Alteplase For Acute Ischemic Stroke: Treatment Outcomes From A Large Northwest Us Stroke Registry (Hall F, Poster Hall; MP8) -  Feb 7, 2023 - Abstract #ISC2023ISC_570;    
    In our study there were no differences in benefit, risk, or treatment logistics between alteplase and tenecteplase when used in treating acute ischemic stroke. Recanalization of large vessel occlusion prior to endovascular thrombectomy was not analyzed but will be the subject of study in this cohort.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Review, Journal:  Replacing Alteplase with Tenecteplase: Is the Time Ripe? (Pubmed Central) -  Feb 7, 2023   
    In this review, we will focus on these recent advances, aiming: (1) to provide a brief overview of thrombolysis in stroke; (2) to provide comparisons between alteplase and TNK for clinical, imaging, and safety outcomes; (3) to focus on key subgroups of interest to understand if there is an advantage of using TNK over alteplase or vice-versa, to review available evidence on role of TNK in intra-arterial thrombolysis, as bridging therapy and in mobile stroke units; and (4) to summarize what to expect in the near future from recently completed trials and propose areas for future research on this evolving topic. We present compelling data from several trials regarding the safety and efficacy of TNK in acute ischemic stroke along with completed yet unpublished trials that will help provide insight into these unanswered questions.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    SAFETY AND EFFICACY OF TENECTEPLASE IN ACUTE ISCHEMIC STROKE () -  Jan 25, 2023 - Abstract #SCCM2023SCCM_1807;    
    While the reason may be due to a broader definition of sICH compared to other studies, there was still a high incidence of clinically significant bleeds that required reversal. Therefore, more evidence on the safety of TNK may be needed before selecting it as the primary treatment of choice for ischemic strokes.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    TENECTEPLASE VERSUS ALTEPLASE FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE () -  Jan 25, 2023 - Abstract #SCCM2023SCCM_1481;    
    Therefore, more evidence on the safety of TNK may be needed before selecting it as the primary treatment of choice for ischemic strokes. Routine use of tenecteplase was found to have similar efficacy and safety to that of alteplase, and a shorter door-to-needle time.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Journal:  Acute and Interventional Treatments. (Pubmed Central) -  Jan 24, 2023   
    There were also additional cost savings and practical advantages including workflow benefits. No abstract available
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Trial completion date, Trial primary completion date:  RESTORE-MI: A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients. (clinicaltrials.gov) -  Jan 20, 2023   
    P3,  N=506, Recruiting, 
    This pivotal trial will provide important data on the role of tenecteplase in acute ischemic stroke, and the use of imaging-based treatment decision making for stroke thrombolysis. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Journal:  Mortality outcomes and predictors of failed thrombolysis following STEMI thrombolysis in a non-PCI capable tertiary hospital: a 5-year analysis. (Pubmed Central) -  Jan 18, 2023   
    Overall, tenecteplase use (aOR 1.749, p = 0.021), pre-existing hypertension (aOR 1.730, p = 0.024), history of stroke (aOR 4.176, p = 0.004), and heart rate ≥ 100 bpm at presentation (aOR 2.333, p < 0.001) were the general predictors of FT...Mortality following STEMI thrombolysis remained high in our population and was attributed to FT. Identified predictors of FT enable early risk stratification to evaluate the patients' prognosis to manage them better.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Trial completion, Trial completion date, Head-to-Head:  TRACEⅡ: Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ (clinicaltrials.gov) -  Jan 17, 2023   
    P3,  N=1430, Completed, 
    Identified predictors of FT enable early risk stratification to evaluate the patients' prognosis to manage them better. Recruiting --> Completed | Trial completion date: Oct 2023 --> Jul 2022
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Review, Journal:  Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke. (Pubmed Central) -  Jan 10, 2023   
    The existing data evaluating the efficacy of TNK compared to alteplase in acute AIS within 4.5 h from symptom onset showed no significant difference between these two agents with regard to functional outcome at 90 days but improved median time to treatment and large vessel recanalization in TNK-treated patients. The results from ongoing TNK trials in larger patient cohorts and in wake-up stroke populations will be instrumental to the wide-scale utilization of TNK in acute AIS management.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Trial completion date, Trial primary completion date:  TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS) (clinicaltrials.gov) -  Jan 5, 2023   
    P3,  N=78, Recruiting, 
    The results from ongoing TNK trials in larger patient cohorts and in wake-up stroke populations will be instrumental to the wide-scale utilization of TNK in acute AIS management. Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Oct 2023 --> Feb 2024
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    INTERESTING CASE OF UNILATERAL NECK SWELLING IN A YOUNG MALE (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_7097;    
    Paget Schroetter Syndrome should be suspected in a young male with symptomatic thrombotic occlusion of subclavian vein and CDT should be considered as a therapeutic option above anticoagulation. Also, stenting should be avoided in these cases.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    POST-INFARCTION VENTRICULAR SEPTAL RUPTURE: NOT JUST A LATE COMPLICATION (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4282;    
    While VSR is a rare complication of MI, it needs to be considered in the unstable post-PCI patient with persistent chest pain and EKG changes. This would allow for earlier diagnosis and treatment for improved survival.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    FACTORS ASSOCIATED WITH DELAY IN STEMI PATIENTS SEEKING MEDICAL ATTENTION (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4132;    
    Special concern should be taken in patients with known cardiac disease. We intend to use this data to target future educational interventions to reduce patient delays to medical care in STEMI and improve the outcomes.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    TWO SPONTANEOUS DISSECTIONS, ONE PATIENT (eAbstract Site) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_3705;    
    To our knowledge, this is the first reported case of concomitant SCAD and Stanford B AAD in a patient with Marfan syndrome. Careful search for high-risk conditions and high-risk pain features led to a proper diagnosis.